Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been considered as a possible therapeutic agent for cancer treatment. This is because of its selective cytotoxicity against various cancer cells without a detrimental effect on normal cells. However, recent studies have reported that the potential application of TRAIL in cancer therapy is limited, as many cancer cells have been found to be resistant to TRAIL. Therefore, small molecule compounds that potentiate the cytotoxicity of TRAIL would be strategic candidates for therapeutic applications in combination with TRAIL. Here we found that a combined treatment of inostamycin and TRAIL synergistically induced caspase-dependent apoptosis in HCT116 cells. Inostamycin upregulated DR5, and a knockdown of DR5 suppressed the apoptosis that was synergistically induced by co-treatment with inostamycin and TRAIL. Moreover, inostamycin increased the expression of DR5 on the cell surface. Therefore, inostamycin-increased cell surface expression of DR5 may have contributed to the enhancement of TRAIL-induced apoptosis. Our study suggests that combined treatment with inostamycin and TRAIL may offer a strategy to overcome TRAIL resistance in tumor cells.
INTRODUCTION
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), also known as Apo2L, is a type II transmembrane protein. TRAIL was originally identified on the basis of sequence homology to the Fas ligand and tumor necrosis factor. 1,2 TRAIL is hypothesized as being a potentially good therapeutic agent for cancer treatment. This is because TRAIL has been shown to induce apoptosis in a variety of tumor cell lines more efficiently than in normal cells. [3] [4] [5] TRAIL exerts its function by binding its receptors, which are expressed on the surface of target cells. To date, four different types of membranebound death receptors for TRAIL has been identified: TRAIL-R1/ DR4, TRAIL-R2/DR5, TRAIL-R3/DcR1 and TRAIL-R4/DcR2. Both DR4 and DR5 have a conserved cytoplasmic region called the 'death domain' . This is a homolog to Fas and tumor necrosis factor-R1, and is required for TRAIL-induced apoptosis. [6] [7] [8] On the other hand, TRAIL also binds to DcR1 and DcR2 that sequester the ligand, but are unable to initiate an apoptosis signal. Thus, DcR1 and DcR2 are considered to be the decoy receptors. 7, 9 The apoptosis signal that is induced by TRAIL has been shown to be similar to that which is induced by Fas. The TRAIL homotrimer induces trimerization of DR5 or DR4 on the surface of target cells, which leads to the formation of death-inducing signaling complex. The trimerization of the death domains results in the recruitment of an adaptor molecule Fas-associated protein with death domain (FADD), which in turn recruits and activates caspase-8. In type I cells, activation of caspase-8 is sufficient for the subsequent activation of effector caspase-3. On the other hand, in type II cells, amplification through the mitochondrial pathway is initiated by the cleavage of Bid by caspase-8. TruncatedBid causes the loss of mitochondrial membrane potential and caspase-9 cleavage, resulting in the activation of caspase-3 and subsequent cellular apoptosis.
The potential application of TRAIL in cancer therapy is currently limited, as many cancer cells have been found to be resistant to the cytotoxic effects of TRAIL. This resistance may be because of the low expression of pro-apoptotic molecules: death receptors or caspase-8. Alternatively, the resistance may be because of the high expression of anti-apoptotic molecules: decoy receptors, FLICE-like-inhibitory protein, inhibitor of apoptosis protein and Bcl-2. Because of the limitations of TRAIL-induced cytotoxicity, the combination of TRAIL with other small molecule compounds has been postulated as strategy to potentiate the cytotoxicity of TRAIL and its therapeutic applications. Indeed, it was reported that several chemotherapeutic agents and natural products, such as CDDP, 10 etoposide, 10,11 doxorubicin, 12 PS-341 (bortezomib), 13 tunicamycin, 14 rottlerin, 15 brandisianins, 16 silibinin 17 and sodium butyrate, 18 were succeeded to cause the sensitization of TRAIL-resistant tumor cells to TRAIL-induced apoptosis.
In this study, we have screened candidate small molecule compounds that synergistically induce apoptosis in the presence of TRAIL. As a result, we found that co-treatment with inostamycin and TRAIL synergistically induced caspase-dependent apoptosis in colorectal cancer HCT116 cells. Inostamycin was isolated from Streptomyces species. MH816-AF15; 19 its structure was shown in Figure 1a . Inostamycin weakly upregulated DR4 and strongly upregulated DR5 expression. Additionally, the synergistic apoptosis that was induced by this co-treatment was completely suppressed in DR5 small interfering RNA (siRNA)-transfected but not in DR4 siRNA-transfected HCT116 cells. Furthermore, inostamycin increased cell surface expression of DR5. Taken together with these results, upregulation of cell surface DR5 by inostamycin possibly contributes to the enhancement of TRAIL-induced apoptosis.
MATERIALS AND METHODS Materials
Inostamycin was prepared as previously described, 19 TRAIL was purchased from Millipore (Billerica, MA, USA). Tunicamycin and z-VAD-fmk were purchased from SIGMA (St. Louis, MO, USA). Rabbit monoclonal antipoly(ADP-ribose) polymerase, rabbit polyclonal anti-caspase-9, anti-caspase-3, anti-Bcl-xL and mouse monoclonal anti-caspase-8 were purchased from Cell Signaling Technology (Beverly, MA, USA). Rabbit polyclonal anti-survivin was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Mouse monoclonal anti-X-linked inhibitor of apoptosis protein (XIAP) was purchased from BD Transduction Laboratories (San Diego, CA, USA). Mouse monoclonal anti-Bcl-2 was purchased from Dako (Carpentaria, CA, USA). Rabbit polyclonal anti-DR5 was purchased from Proscience (Poway, CA, USA). Rabbit polyclonal anti-DR4 was purchased from Millipore. Mouse monoclonal anti-C/EBP homologous protein (CHOP) was purchased from Thermo scientific (Rockford, IL, USA). Mouse monoclonal anti-DR5 phycoerythrin (PE)-conjugated was purchased from eBioscience (San Diego, CA, USA). Horseradish peroxidase-conjugated anti-mouse IgG and anti-rabbit IgG secondary antibodies were purchased from GE Healthcare (Little Chalfont, UK).
Cell culture
Human colorectal carcinoma HCT116 cells, HT29 cells and human small cell lung cancer Ms-1 cells were maintained in Roswell Park Memorial Institute medium (Nissui, Tokyo, Japan) supplemented with 5% fetal bovine serum. Human cervical cancer HeLa cells were maintained in Dulbecco's modified Eagle's medium (Nissui, Tokyo, Japan) supplemented with 8% fetal bovine serum. Human prostate adenocarcinoma LNCaP cells were maintained in Roswell Park Memorial Institute medium supplemented with 10% fetal bovine serum-Roswell Park Memorial Institute medium. 
Trypan blue exclusion assay

Propidium iodide staining
Propidium iodide staining and flow cytometry were used to determine the degree of cellular apoptosis. HCT116 cells were seeded in 6-well plates and incubated overnight before experiment. The cells were treated with TRAIL with or without inostamycin for 18 h. Floating and adherent cells were collected and resuspended in PBS À . Cold ethanol was added in a dropwise manner while vortexing to fix the cells. Fixed cells were collected and resuspended in PBScontaining 50 mg ml À1 propidium iodide. Flow cytometry was done using 
Western blotting
Cells were lysed with a lysis buffer containing 25 mM HEPES (pH 7.8), 1.5% Triton-X 100, 1.0% sodium deoxycholate, 0.1% SDS, 0.5 M NaCl, 5 mM EDTA, 50 mM NaF, 100 mM Na 3 VO 4 , 0.1 mg ml À1 leupeptin and 1 mM phenylmethylsulfonyl fluoride. Proteins were separated by SDS-polyacryalamide gel electrophoresis and transferred to a polyvinylidene fluoride membrane (Millipore). After the membranes had been incubated with primary and secondary antibodies, the immune complexes were detected with an Immobilon Western kit (Millipore), and the luminescence was detected with a LAS-1000 mini (Fujifilm, Tokyo, Japan). 
Real-time reverse transcriptase (RT)-PCR analysis
RNA interference
siRNA for control (12935-300), CHOP (5 0 -CCUCACUCUCCAGAUUCCA GUCAGA-3 0 ) DR4 (HSS112945) and DR5 (HSS112939) were purchased from Invitrogen. HCT116 cells were transfected with siRNA using HiPerFect (QIAGEN, Hilden, Germany), according to the manufacturer's instructions.
Cell surface staining of DR5
HCT116 cells were seeded in 6-well plates and incubated overnight before the experiment. Cells were then treated with inostamycin for 12 h. Cells were then collected and resuspended in PBS À including PE-conjugated DR5 antibody. After incubation for 1 h at 4 1C, the cells were washed with PBS -twice and resuspended in PBS À . Flow cytometry analysis was performed with EPICS (Beckman Coulter).
RESULTS AND DISCUSSION
Co-treatment with inostamycin and TRAIL synergistically induced apoptosis in HCT116 cells In this study, we first found that co-treatment with inostamycin and TRAIL synergistically induced cytotoxicity in HCT116 cells. As shown in Figure 1b , although neither 10 ng ml À1 TRAIL nor 1 mg ml À1 inostamycin alone showed cytotoxicity in HCT116 cells after 18 h treatment, the cell viability was decreased to about 40% when HCT116 cells were treated with inostamycin and TRAIL in combination. The synergistic cytotoxicity occurred in inostamycin and TRAIL dose-dependent manner. This synergistic effect is cell type-dependent, and is observed in HeLa cells, HT29 cells and LNCaP cells but not in Ms-1 cells (Figure 1b) . Flow cytometer analysis demonstrated that the synergistic increase of the Sub-G 1 population was observed in co-treatment with inostamycin and TRAIL in HCT116 cells (Figure 1c) . Furthermore, a one hour preincubation with the pancaspase inhibitor 100 mM z-VAD-fmk suppressed the cell death that was induced by co-treatment with inostamycin and TRAIL (Figure 1c) . We also observed the cleavage of caspase-8, caspase-9, caspase-3 and poly(ADP-ribose) polymerase, a well known substrate of caspase-3, at 6 h after inostamycin and TRAIL co-treatment (Figure 1d ). In contrast, the cleaved caspase-8, caspase-9, caspase-3 and poly(ADP-ribose) polymerase were only weakly detected when HCT116 cells were treated with 10 ng ml À1 of TRAIL alone. Inostamycin alone also could not activate caspase-8, caspase-9 or caspase-3 in HCT116 cells (Figure 1d ). These results suggested that co-treatment with inostamycin and TRAIL induced caspase-dependent apoptosis.
Inostamycin enhanced TRAIL-induced apoptosis possibly through DR5 upregulation on the cell surface TRAIL-stimulated death signal is initiated by the binding of TRAIL to DR4 or DR5, which resulted in the subsequent activation of caspase-8. As shown in Figure 2a , western blotting analysis using an anti-DR4 or anti-DR5 antibody showed that inostamycin strongly upregulated the DR5 protein in HCT116 cells, it also slightly upregulated the DR4 protein (Figure 2a) . Similarly, inostamycin-induced DR5 upregulation was also observed in HT29 cells and HeLa cells, in which co-treatment with inostamycin and TRAIL induced synergistic cytotoxicity (Figure 2a) . Inostamycin-induced DR5 protein was detected as two bands, which were likely products of alternative splice variants of the DR5 gene 20, 21 Furthermore, under the condition where inostamycinupregulated DR4 or -DR5 protein was efficiently reduced by transient transfection of DR4 siRNA or DR5 siRNA (Figure 2b) , apoptosis induced by co-treatment with inostamycin and TRAIL was completely suppressed in DR5 siRNA-transfected HCT116 cells, but not in DR4 siRNA-transfected HCT116 cells (Figure 2c ). These results indicated that DR5 is indispensable for the apoptosis induced by co-treatment with inostamycin and TRAIL. Moreover, inostamycin induced cell surface expression of DR5 in a time-dependent manner (Figure 2d ). On the other hand, the protein expression of four anti-apoptotic molecules, Bcl-2, Bcl-xL, XIAP and survivin, was unaffected by inostamycin in HCT116 cells (Figure 2e ). Considering that it increases the cell surface expression of DR5, it is likely that inostamycinincreased cell surface expression of DR5 contributes to TRAIL sensitization.
Inostamycin-induced transcription of DR5 was regulated by CHOP. As shown in Figure 3a , inostamycin-induced increases in DR5 mRNA levels were evaluated by real-time RT-PCR analysis. This data suggests that inostamycin activates transcription of DR5 in HCT116 cells. Recent studies have reported that tunicamycin-induced 14 and MG132-induced 22 CHOP (C/EBP homologous protein) upregulation activates DR5 transcription through CHOP-binding site in DR5 promoter region. This results in a sensitization of TRAIL-induced apoptosis. As we also found that 1 mg ml À1 inostamycin increased CHOP protein expression with similar time-course kinetics to DR5 upregulation (Figure 3b) , we next examined whether this inostamycininduced CHOP expression regulated DR5 transcription. When CHOP was successfully silenced by transient transfection of siRNA for CHOP (siCHOP) (Figure 3c ), inostamycin-increased DR5 mRNA was markedly suppressed (Figure 3d) . Furthermore, as consistent with previous report, tunicamycin-increased expression of DR5 mRNA was also completely suppressed in siCHOP-transfected HCT116 cells (Figure 3d ). Next, we examined whether inostamycin-induced DR5 protein upregulation was also suppressed in CHOP-knockdown HCT116 cells. As shown in Figures 4a and b , neither inostamycininduced DR5 protein expression nor inostamycin-increased cell surface expression of DR5 was suppressed under the conditions where tunicamycin-induced DR5 protein expression was completely suppressed in CHOP-knockdown cells. Furthermore, the transient transfection with siCHOP could not suppress apoptosis induction by the synergistic effect of co-treatment with inostamycin and TRAIL (Figure 4c) . When considered together, our results suggest that inostamycin enhanced TRAIL-induced apoptosis possibly because of a CHOPindependent upregulation of DR5 on the cell surface. At present, the mechanism by which inostamycin upregulates DR5 protein expression remains unclear. However, these results were consistent with our conclusion that the inostamycin-increased cell surface expression of DR5 possibly contributes to the enhancement of TRAIL-induced apoptosis.
In a previous study, various small molecule compounds, such as tunicamycin, 14 were reported to transactivate the DR5 gene by the upregulation of CHOP. The inostamycin-induced increase in DR5 mRNA was suppressed in CHOP-knockdown HCT116 cells; however, DR5 protein expression was not suppressed. Furthermore, knockdown of CHOP by siCHOP suppressed only inostamycinincreased CHOP-dependent DR5 mRNA expression, but constitutively expressed DR5 mRNA levels were not affected (Figure 3d) . Therefore, in siCHOP-transfected HCT116 cells, inostamycin is considered to increase the protein levels of DR5 translated from constitutively expressed DR5 mRNA by posttranslational modulation. Various studies have reported the mechanism of the transcriptional activation of DR5 gene. However, little is known about the mechanism of translation, posttranslational modification, localization or degradation of DR5. Because of the data presented in this study, inostamycin may be a good bioprobe for use in investigating the regulatory mechanism of DR5 protein. Furthermore, elucidation of the mechanism by which inostamycin increases the expression of DR5 on the cell surface may provide a new molecular target for inducing DR5 upregulation to overcome TRAIL resistance. HCT116 cells were transiently transfected with 20 nM siCHOP. After incubation for 24 h, the transfected cells were treated with or without 1 mg ml À1 INM together with 10 ng ml À1 TRAIL for 18 h. The cells were stained with propidium iodide (PI), and sub-G 1 phase cells were detected using a flow cytometer.
